Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
YK-11
Also known as: Myostine
YK-11 is a steroidal SARM that also acts as a myostatin inhibitor. It is structurally related to DHT and has a unique dual mechanism. Almost all data comes from cell studies, with virtually no animal or human trials.
Risk Level
High RiskDifficulty
Advanced| CAS Number | 1370003-76-1 |
| Molecular Formula | C25H34O6 |
| Class | SARM |
| Category | SARMs |
Mechanism of Action
YK-11 selectively activates androgen receptors and simultaneously inhibits myostatin by increasing follistatin expression. This dual mechanism theoretically allows for muscle growth beyond natural genetic limits. Its steroidal backbone distinguishes it from other SARMs.
Dosing Research
No clinical dosing data exists. Research community references 5-10 mg/day. Half-life estimated at 6-10 hours. Cycles typically 6-8 weeks due to unknown safety profile.
Side Effects & Risks
Essentially unknown due to lack of animal or human studies. Theoretical risks include liver toxicity due to methylated steroidal structure, hormonal suppression, and joint issues from myostatin inhibition. High-risk compound.
Research Studies
Related compounds
Ostarine
SARMOstarine is the most widely studied SARM, originally developed for muscle wasting and osteoporosis. It has completed multiple Phase II and Phase III clinical trials, making it one of the few SARMs with substantial human data.
Ligandrol
SARMLigandrol is a non-steroidal SARM developed by Ligand Pharmaceuticals for muscle wasting conditions. It demonstrated significant lean mass gains in Phase I trials at doses as low as 1 mg/day.
Cardarine
OtherCardarine is not actually a SARM but a PPARδ agonist, often grouped with SARMs commercially. It was developed by GlaxoSmithKline for metabolic and cardiovascular diseases but was abandoned due to cancer findings in rodent studies.
RAD-140
SARMRAD-140 is a potent non-steroidal SARM developed by Radius Health. It has shown neuroprotective properties in preclinical studies and is currently in early clinical trials for breast cancer.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.